Zhenshu Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhenshu Xu has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Han Liu
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publications Wenjie Zhang
Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
7 shared publicationsJinlan Long
Fujian Provincial Key Laboratory on Hematology Fujian Institute of Hematology Fujian Medical University Union Hospital Fuzhou China
6 shared publicationsRong Zhan
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
6 shared publicationsChaoqun Lu
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publicationsHuajian Xian
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells
Background: The therapeutic efficacy of chimeric antigen receptor T (CAR-T) cells targeting CD19 in chronic lymphocytic leukemia (CLL) treatment can be limited by target cell antigen loss. This study aims to elucidate how the intrinsic NOTCH1 signaling activity in CLL cells modulates their sensitivity to CD19-targeted CAR-T cell therapy. Methods: In this study, we modulated NOTCH1 signaling in MEC-1 cells through gene knockout and pharmacological inhibition, and employed molecular and cellular biology techniques to elucidate the mechanism by which NOTCH1 regulates CD19 degradation. On this basis, we evaluated the effect of combining NOTCH1 inhibition on enhancing the efficacy of CD19 CAR-T therapy both in vitro and in vivo. Results: NOTCH1 deficiency in MEC-1 cells profoundly enhanced potency of CD19 CAR-T cell-mediated killing. Mechanistically, upon CAR-T cell engagement, NOTCH1 signaling in target cells promoted the rapid lysosomal degradation of the CD19 antigen. This was achieved through its downstream effector HEY1, which transcriptionally represses RAB31. The downregulation of RAB31, a negative regulator of the late endosome/lysosome transporter RAB7, was essential for facilitating CD19 degradation. Both NOTCH1-deficient and pharmacologically inhibited CLL cells exhibited impaired CD19 degradation, higher surface antigen retention, and increased susceptibility to CAR-T cell killing, correlating with elevated CAR-T cell activation and effector molecule secretion. Conclusions: This study identifies NOTCH1 signaling as a key negative regulator of CD19 stability in CLL, as this pathway promotes the lysosomal degradation of CD19 following its internalization. Therefore, targeting this pathway represents a potential strategy to enhance the efficacy of CD19 CAR-T therapy in the treatment of CLL.
- 27 September 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
Open AccessTargeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells
Background: The therapeutic efficacy of chimeric antigen receptor T (CAR-T) cells targeting CD19 in chronic lymphocytic leukemia (CLL) treatment can be limited by target cell antigen loss. This study aims to elucidate how the intrinsic NOTCH1 signaling activity in CLL cells modulates their sensitivity to CD19-targeted CAR-T cell therapy. Methods: In this study, we modulated NOTCH1 signaling in MEC-1 cells through gene knockout and pharmacological inhibition, and employed molecular and cellular biology techniques to elucidate the mechanism by which NOTCH1 regulates CD19 degradation. On this basis, we evaluated the effect of combining NOTCH1 inhibition on enhancing the efficacy of CD19 CAR-T therapy both in vitro and in vivo. Results: NOTCH1 deficiency in MEC-1 cells profoundly enhanced potency of CD19 CAR-T cell-mediated killing. Mechanistically, upon CAR-T cell engagement, NOTCH1 signaling in target cells promoted the rapid lysosomal degradation of the CD19 antigen. This was achieved through its downstream effector HEY1, which transcriptionally represses RAB31. The downregulation of RAB31, a negative regulator of the late endosome/lysosome transporter RAB7, was essential for facilitating CD19 degradation. Both NOTCH1-deficient and pharmacologically inhibited CLL cells exhibited impaired CD19 degradation, higher surface antigen retention, and increased susceptibility to CAR-T cell killing, correlating with elevated CAR-T cell activation and effector molecule secretion. Conclusions: This study identifies NOTCH1 signaling as a key negative regulator of CD19 stability in CLL, as this pathway promotes the lysosomal degradation of CD19 following its internalization. Therefore, targeting this pathway represents a potential strategy to enhance the efficacy of CD19 CAR-T therapy in the treatment of CLL.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1687242
Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity
Background: While blinatumomab has demonstrated substantial efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), the therapeutic potential of combining blinatumomab with tyrosine kinase inhibitors (TKIs) and low-dose chemotherapy as frontline induction for newly diagnosed Philadelphia chromosome-positive B-ALL (Ph + B-ALL) remains systematically underexplored. This study aims to evaluate the efficacy and safety of blinatumomab in combination with low-dose chemotherapy for induction treatment of newly diagnosed Ph + B-ALL. Methods: A retrospective analysis was performed on 24 newly diagnosed cases of Ph + B-ALL admitted to the Department of Hematology at our institution, between April 2023 and April 2025. Result: The median age was 51.1 years in the blinatumomab group ( n = 11) and 42.6 years in the conventional chemotherapy group ( n = 13). All 24 patients attained CR after one cycle of induction chemotherapy. The MRD negativity rate showed a trend toward improvement in the blinatumomab group compared with the conventional chemotherapy group (81.8% [9/11] vs. 46.2% [6/13]). The median BCR::ABL1 level was 0.10 (range: 0.00–0.56) in the blinatumomab group versus 2.13 (range: 0.25–9.21) in the conventional chemotherapy group. The mean log reduction in the BCR::ABL1 gene level in the blinatumomab group was 3.09 ± 0.95, which was greater than in the conventional chemotherapy group (1.64 ± 0.83). At a median follow-up of approximately 13.8 months, no relapses occurred in the blinatumomab group versus 5 relapses (38.5%) in the conventional group. We documented a significant improvement in 12-month disease-free survival (DFS) rate with the blinatumomab regimen (90.9%) compared to conventional chemotherapy (46.2%). Patients receiving blinatumomab experienced markedly reduced hematologic toxicity, manifested by a shorter duration of neutropenia (2.8 ± 2.4 vs. 6.2 ± 4.4 days), a lower incidence of bleeding (0% vs. 53.8%), and a lower rate of infections (36.4% vs. 69.2%). This improved safety profile was accompanied by a significantly lower transfusion burden, as evidenced by the consumption of fewer units of platelets (1.61 ± 1.63 vs. 4.33 ± 2.90) and red blood cells (2.14 ± 2.07 vs. 6.15 ± 4.85). Conclusion: Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1687242
Open AccessBlinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity
Background: While blinatumomab has demonstrated substantial efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), the therapeutic potential of combining blinatumomab with tyrosine kinase inhibitors (TKIs) and low-dose chemotherapy as frontline induction for newly diagnosed Philadelphia chromosome-positive B-ALL (Ph + B-ALL) remains systematically underexplored. This study aims to evaluate the efficacy and safety of blinatumomab in combination with low-dose chemotherapy for induction treatment of newly diagnosed Ph + B-ALL. Methods: A retrospective analysis was performed on 24 newly diagnosed cases of Ph + B-ALL admitted to the Department of Hematology at our institution, between April 2023 and April 2025. Result: The median age was 51.1 years in the blinatumomab group ( n = 11) and 42.6 years in the conventional chemotherapy group ( n = 13). All 24 patients attained CR after one cycle of induction chemotherapy. The MRD negativity rate showed a trend toward improvement in the blinatumomab group compared with the conventional chemotherapy group (81.8% [9/11] vs. 46.2% [6/13]). The median BCR::ABL1 level was 0.10 (range: 0.00–0.56) in the blinatumomab group versus 2.13 (range: 0.25–9.21) in the conventional chemotherapy group. The mean log reduction in the BCR::ABL1 gene level in the blinatumomab group was 3.09 ± 0.95, which was greater than in the conventional chemotherapy group (1.64 ± 0.83). At a median follow-up of approximately 13.8 months, no relapses occurred in the blinatumomab group versus 5 relapses (38.5%) in the conventional group. We documented a significant improvement in 12-month disease-free survival (DFS) rate with the blinatumomab regimen (90.9%) compared to conventional chemotherapy (46.2%). Patients receiving blinatumomab experienced markedly reduced hematologic toxicity, manifested by a shorter duration of neutropenia (2.8 ± 2.4 vs. 6.2 ± 4.4 days), a lower incidence of bleeding (0% vs. 53.8%), and a lower rate of infections (36.4% vs. 69.2%). This improved safety profile was accompanied by a significantly lower transfusion burden, as evidenced by the consumption of fewer units of platelets (1.61 ± 1.63 vs. 4.33 ± 2.90) and red blood cells (2.14 ± 2.07 vs. 6.15 ± 4.85). Conclusion: Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
- Open Access
- 20 August 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-17
Exploration of biomarkers for predicting the prognosis of patients with diffuse large B-cell lymphoma by machine-learning analysis
As one distinct origin of hematological malignancies, diffuse large B-cell lymphoma (DLBCL) has caused a major public health problem. However, the molecular mechanisms that underlie this association have not been clearly elucidated. To improve this situation, it is urgent to explore disease-specific diagnostic biomarkers and mechanisms. Three microarray datasets (GSE25638, GSE12195 and GSE12453) were downloaded from the Gene Expression Omnibus (GEO) database. The key genes in DLBCL patients were screened by differentially expression gene (DEG) and weighted gene co-expression network analysis (WGCNA). Functional enrichment analysis and protein-protein interaction (PPI) network construction were employed to reveal DLBCL-related pathogenic molecules and underlying mechanisms. Candidate biomarkers were screened using random forest (RF) analysis. A diagnostic nomogram and Kaplan-Meier (KM) survival analysis were constructed to predict the risk of patients. Single-sample gene set enrichment analysis (ssGSEA) was used for exploring immune cell infiltration in lymphoma. The validation of the hub genes expressions was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) tests. A total of 95 key genes were acquired from three datasets of DLBCL patients by DEG analysis and WGCNA. DEGs were significantly enriched in pathways associated with inflammatory response, biological process involved in interspecies interaction between organisms, C-X-C chemokine receptor binding as well as chemokine activity. This was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. Moreover, four hub genes (CXCL9, CCL18, C1QA and CTSC) were significantly screened from the three datasets using RF algorithms. They were closely correlated with the overall survival of DLBCL patients. The dysregulated infiltration of immune cells, including natural killer (NK) cells and T cells, were positively linked to the expression levels of the four hub genes. The receiver operating characteristic (ROC) results were promising via the construction of a nomogram model. Additionally, the increased expression of the four key genes was further verified in DLBCL patients. Four crucial hub genes (CXCL9, CCL18, C1QA and CTSC) that could predict the risk of DLBCL were systematically identified. In particular, CXCL9 may be the most important potential biomarker for the progression of DLBCL patients.
- 20 August 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-17
Open AccessExploration of biomarkers for predicting the prognosis of patients with diffuse large B-cell lymphoma by machine-learning analysis
As one distinct origin of hematological malignancies, diffuse large B-cell lymphoma (DLBCL) has caused a major public health problem. However, the molecular mechanisms that underlie this association have not been clearly elucidated. To improve this situation, it is urgent to explore disease-specific diagnostic biomarkers and mechanisms. Three microarray datasets (GSE25638, GSE12195 and GSE12453) were downloaded from the Gene Expression Omnibus (GEO) database. The key genes in DLBCL patients were screened by differentially expression gene (DEG) and weighted gene co-expression network analysis (WGCNA). Functional enrichment analysis and protein-protein interaction (PPI) network construction were employed to reveal DLBCL-related pathogenic molecules and underlying mechanisms. Candidate biomarkers were screened using random forest (RF) analysis. A diagnostic nomogram and Kaplan-Meier (KM) survival analysis were constructed to predict the risk of patients. Single-sample gene set enrichment analysis (ssGSEA) was used for exploring immune cell infiltration in lymphoma. The validation of the hub genes expressions was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) tests. A total of 95 key genes were acquired from three datasets of DLBCL patients by DEG analysis and WGCNA. DEGs were significantly enriched in pathways associated with inflammatory response, biological process involved in interspecies interaction between organisms, C-X-C chemokine receptor binding as well as chemokine activity. This was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. Moreover, four hub genes (CXCL9, CCL18, C1QA and CTSC) were significantly screened from the three datasets using RF algorithms. They were closely correlated with the overall survival of DLBCL patients. The dysregulated infiltration of immune cells, including natural killer (NK) cells and T cells, were positively linked to the expression levels of the four hub genes. The receiver operating characteristic (ROC) results were promising via the construction of a nomogram model. Additionally, the increased expression of the four key genes was further verified in DLBCL patients. Four crucial hub genes (CXCL9, CCL18, C1QA and CTSC) that could predict the risk of DLBCL were systematically identified. In particular, CXCL9 may be the most important potential biomarker for the progression of DLBCL patients.
- Open Access
- 27 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1531344
Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion
Background: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective for treating relapsed or refractory acute B cell leukemia. However, challenges such as cytokine release syndrome, T cell dysfunction, and exhaustion persist. Enhancing CAR-T cell efficacy through changing CAR internalization and recycling is a promising approach. The transmembrane domain is the easiest motif to optimize for modulating CAR internalization and recycling without introducing additional domains, and its impact on CAR internalization and recycling has not yet been thoroughly explored. In this study, we aim to enhance CAR-T cell function by focusing on the solely transmembrane domain design.Methods: Utilizing plasmid construction and lentivirus generation, we get two different transmembrane CAR-T cells [19CAR-T(1a) and 19CAR-T(8α)]. Through co-culture with tumor cells, we evaluate CAR dynamic change, activation levels, exhaustion markers, mitochondrial function, and differentiation in both CAR-T cells. Furthermore, immunofluorescence microscopy analysis is performed to reveal the localization of internalized CAR molecules. RNA sequencing is used to detect the transcriptome of activated CAR-T cells. Finally, a mouse study is utilized to verify the anti-tumor efficacy of 19CAR-T(1a) cells in vivo.Results: Our findings demonstrate that 19CAR-T(1a) has lower surface CAR expression, faster internalization, and a higher recycling rate compared to 19CAR-T(8α). Internalized 19CAR(1a) co-localizes more with early and recycling endosomes, and less with lysosomes than 19CAR(8α). These features result in lower activation levels, less cytokine release, and reduced exhaustion markers in 19CAR-T(1a). Furthermore, CAR-T cells with CD1a transmembrane domain also exhibit a superior anti-tumor ability and reduced exhaustion in vivo.Conclusion: Overall, we demonstrate that the transmembrane domain plays a critical role in CAR-T cell function. An optimized transmembrane domain can alleviate cytokine release syndrome and reduce CAR-T cell exhaustion, providing a direction for CAR design to enhance CAR-T cell function.
- 27 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1531344
Open AccessImproved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion
Background: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective for treating relapsed or refractory acute B cell leukemia. However, challenges such as cytokine release syndrome, T cell dysfunction, and exhaustion persist. Enhancing CAR-T cell efficacy through changing CAR internalization and recycling is a promising approach. The transmembrane domain is the easiest motif to optimize for modulating CAR internalization and recycling without introducing additional domains, and its impact on CAR internalization and recycling has not yet been thoroughly explored. In this study, we aim to enhance CAR-T cell function by focusing on the solely transmembrane domain design.Methods: Utilizing plasmid construction and lentivirus generation, we get two different transmembrane CAR-T cells [19CAR-T(1a) and 19CAR-T(8α)]. Through co-culture with tumor cells, we evaluate CAR dynamic change, activation levels, exhaustion markers, mitochondrial function, and differentiation in both CAR-T cells. Furthermore, immunofluorescence microscopy analysis is performed to reveal the localization of internalized CAR molecules. RNA sequencing is used to detect the transcriptome of activated CAR-T cells. Finally, a mouse study is utilized to verify the anti-tumor efficacy of 19CAR-T(1a) cells in vivo.Results: Our findings demonstrate that 19CAR-T(1a) has lower surface CAR expression, faster internalization, and a higher recycling rate compared to 19CAR-T(8α). Internalized 19CAR(1a) co-localizes more with early and recycling endosomes, and less with lysosomes than 19CAR(8α). These features result in lower activation levels, less cytokine release, and reduced exhaustion markers in 19CAR-T(1a). Furthermore, CAR-T cells with CD1a transmembrane domain also exhibit a superior anti-tumor ability and reduced exhaustion in vivo.Conclusion: Overall, we demonstrate that the transmembrane domain plays a critical role in CAR-T cell function. An optimized transmembrane domain can alleviate cytokine release syndrome and reduce CAR-T cell exhaustion, providing a direction for CAR design to enhance CAR-T cell function.
- Open Access
- 3 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-12
A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma
Survival prediction accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in extra-nodal natural killer/T-cell lymphoma (ENKTL) is controversial. This study aimed to evaluate the prognostic value of 18F-FDG PET/CT parameters including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), and to develop a new prognostic model for ENKTL. We analyzed 390 ENKTL patients with comprehensive clinical and survival data. All patients received asparaginase-based chemotherapy with or without radiotherapy, or radiotherapy alone. Metabolic tumor volume (MTV) was calculated using a 41% SUVmax threshold, and TLG was computed as MTV multiplied by the average SUV. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier curves and compared with log-rank tests. Optimal cut-off values were determined using the Youden’ index. Cox regression analysis identified significant prognostic factors. A nomogram predicting 1-, 3-, and 5-year survival was developed and validated using the C-index and calibration curves. Statistical significance was set at p < 0.05. Of the 390 patients, 262 (67.2%) were included in the training set and 128 (32.8%) in the validation set. 18F-FDG PET-CT parameters with cutoff values of SUVmax > 12.8, TMTV > 16.4 cm3, and TLG > 137.0, were significantly associated with poorer OS (p = 0.009) and PFS (p = 0.003). Multivariable Cox regression identified the following as independent predictors of worse OS: age > 60 years (HR = 1.923, 95% CI: 1.001—3.693), presence of B symptoms (HR = 1.861, 1.132—3.059), ECOG score ≥ 2 (HR = 2.076, 1.165—3.699), extranodal involvement ≥ 2 sites (HR = 2.349, 1.384—3.988), bone marrow involvement (HR = 4.884, 2.137—11.163), SUVmax > 12.8 (HR = 2.226, 1.260—3.930), and TMTV > 16.4 cm3 (HR = 1.854, 1.093—3.147). The new prognostic model achieved a C-index of 0.772 for OS and 0.750 for PFS in the training set, and 0.777 for OS and 0.696 for PFS in the validation set. Area under the curve (AUC) values for 1-, 3-, and 5-year OS were 0.841, 0.804, and 0.767 in the training set, and 0.718, 0.786, and 0.893 in the validation set. Risk stratification divided patients into four groups with significant differences in survival (p < 0.001). SUVmax, TMTV, and TLG are independent prognostic factors in ENKTL. Our new model, which integrates 18F-FDG PET/CT metrics with clinical data, enhances survival prediction and may support personalized treatment strategies, though further validation is required.
- 3 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-12
Open AccessA novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma
Survival prediction accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in extra-nodal natural killer/T-cell lymphoma (ENKTL) is controversial. This study aimed to evaluate the prognostic value of 18F-FDG PET/CT parameters including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), and to develop a new prognostic model for ENKTL. We analyzed 390 ENKTL patients with comprehensive clinical and survival data. All patients received asparaginase-based chemotherapy with or without radiotherapy, or radiotherapy alone. Metabolic tumor volume (MTV) was calculated using a 41% SUVmax threshold, and TLG was computed as MTV multiplied by the average SUV. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier curves and compared with log-rank tests. Optimal cut-off values were determined using the Youden’ index. Cox regression analysis identified significant prognostic factors. A nomogram predicting 1-, 3-, and 5-year survival was developed and validated using the C-index and calibration curves. Statistical significance was set at p < 0.05. Of the 390 patients, 262 (67.2%) were included in the training set and 128 (32.8%) in the validation set. 18F-FDG PET-CT parameters with cutoff values of SUVmax > 12.8, TMTV > 16.4 cm3, and TLG > 137.0, were significantly associated with poorer OS (p = 0.009) and PFS (p = 0.003). Multivariable Cox regression identified the following as independent predictors of worse OS: age > 60 years (HR = 1.923, 95% CI: 1.001—3.693), presence of B symptoms (HR = 1.861, 1.132—3.059), ECOG score ≥ 2 (HR = 2.076, 1.165—3.699), extranodal involvement ≥ 2 sites (HR = 2.349, 1.384—3.988), bone marrow involvement (HR = 4.884, 2.137—11.163), SUVmax > 12.8 (HR = 2.226, 1.260—3.930), and TMTV > 16.4 cm3 (HR = 1.854, 1.093—3.147). The new prognostic model achieved a C-index of 0.772 for OS and 0.750 for PFS in the training set, and 0.777 for OS and 0.696 for PFS in the validation set. Area under the curve (AUC) values for 1-, 3-, and 5-year OS were 0.841, 0.804, and 0.767 in the training set, and 0.718, 0.786, and 0.893 in the validation set. Risk stratification divided patients into four groups with significant differences in survival (p < 0.001). SUVmax, TMTV, and TLG are independent prognostic factors in ENKTL. Our new model, which integrates 18F-FDG PET/CT metrics with clinical data, enhances survival prediction and may support personalized treatment strategies, though further validation is required.
- Open Access
- 1 March 2025
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 18 (1) , 1-4
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.
- 1 March 2025
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 18 (1) , 1-4
Open AccessBCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.
- Open Access
- 23 January 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-14
ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2
Background: Lung cancer, particularly non-small cell lung cancer (NSCLC), has high recurrence rates and remains a leading cause of cancer-related death, despite recent advances in its treatment. Emerging therapies, such as chimeric antigen receptor (CAR)-T cell therapy, have shown promise but face significant challenges in targeting solid tumors. This study investigated the potential of combining receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting CAR-T cells with ferroptosis inducers to promote ferroptosis of tumor cells and enhance anti-tumor efficacy. Methods: RNA-seq data and immunofluorescence analysis of relapsed NSCLC patient samples were used to explore ROR1 expression. In addition, ROR1-targeting CAR-T cells were developed to assess cytotoxic activity against ROR1+ tumor cells, and the effect of cytokine stimulation on their efficacy was evaluated. Lipidomics, immunofluorescent histochemistry, and western blotting were used to explore the observed effects. Ferroptosis indicators, including levels of reactive oxygen species, were used to detect the combined effect of CAR-T cells and ferroptosis-inducing drugs. Finally, tumor-bearing mice were used to validate the in vivo efficacy of the combination therapy strategy. Results: Tumor cells treated with ferroptosis inducers showed increased sensitivity to Interferon gamma (IFN-γ) secreted by ROR1 CAR-T cells. Furthermore, ROR1 CAR-T cells enhanced the production of phosphatidylcholine with diacyl-polyunsaturated fatty acid tails (PC-PUFA2) by working in tandem with IFN-γ. This enhancement promoted the expression of acyl-CoA synthetase long chain family member 4 (ACSL4), which in turn strengthened the overall anti-tumor response. Conclusions: Combining ROR1 CAR-T cells with ferroptosis inducers enhanced anti-tumor efficacy in NSCLC by promoting ferroptosis through increased lipid peroxidation.
- 23 January 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-14
Open AccessROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2
Background: Lung cancer, particularly non-small cell lung cancer (NSCLC), has high recurrence rates and remains a leading cause of cancer-related death, despite recent advances in its treatment. Emerging therapies, such as chimeric antigen receptor (CAR)-T cell therapy, have shown promise but face significant challenges in targeting solid tumors. This study investigated the potential of combining receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting CAR-T cells with ferroptosis inducers to promote ferroptosis of tumor cells and enhance anti-tumor efficacy. Methods: RNA-seq data and immunofluorescence analysis of relapsed NSCLC patient samples were used to explore ROR1 expression. In addition, ROR1-targeting CAR-T cells were developed to assess cytotoxic activity against ROR1+ tumor cells, and the effect of cytokine stimulation on their efficacy was evaluated. Lipidomics, immunofluorescent histochemistry, and western blotting were used to explore the observed effects. Ferroptosis indicators, including levels of reactive oxygen species, were used to detect the combined effect of CAR-T cells and ferroptosis-inducing drugs. Finally, tumor-bearing mice were used to validate the in vivo efficacy of the combination therapy strategy. Results: Tumor cells treated with ferroptosis inducers showed increased sensitivity to Interferon gamma (IFN-γ) secreted by ROR1 CAR-T cells. Furthermore, ROR1 CAR-T cells enhanced the production of phosphatidylcholine with diacyl-polyunsaturated fatty acid tails (PC-PUFA2) by working in tandem with IFN-γ. This enhancement promoted the expression of acyl-CoA synthetase long chain family member 4 (ACSL4), which in turn strengthened the overall anti-tumor response. Conclusions: Combining ROR1 CAR-T cells with ferroptosis inducers enhanced anti-tumor efficacy in NSCLC by promoting ferroptosis through increased lipid peroxidation.
- Open Access
- 23 January 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (6) , 1412-1416
The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
- 23 January 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (6) , 1412-1416
Open AccessThe nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
- Open Access
- 7 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma
This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed. Whether in all selected patients or in groups R-ISS II-III, there was a notable increase in the proportion of patients achieving in a very good partial response (VGPR) or better (P < 0.001, P = 0.02) and a complete response (CR) or better (P = 0.007, P = 0.014) after transplantation compared to the pre-transplant status. Post-Transplant Immune Reconstitution Analysis (Baseline vs. Pre-Transplant and Pre-Transplant vs. Post-Transplant): The level of CD19 + B cells, CD20 + B cells, CD22 + B cells, CD3 + T cells, IgG and LMR showed the same change trend, that is, it decreased before transplantation (P < 0.001, P < 0.001, P < 0.001, P < 0.001, PP < 0.001) and then increased significantly after transplantation(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). CD3 + CD4 + T cells from 545.97 (342.11,708.60)/µL to 342.93 (168.38, 475.52)/µL (P < 0.001) and then to 251.48 (188.52, 406.98)/µL (P = 0.348); CD3 + CD8 + T cells from 391.36 (242.19, 563.37)/µL to 337.23 (192.54, 505.96)/µL (P = 0.065) and then to 797.96 (514.49, 1198.03)/µL (P < 0.001), so the CD3 + CD4+/CD3 + CD8 + T cell ratio still remained inverted post-transplant. NK cells changed from 309.86 (206.33, 460.96)/µL to 258.31 (160.75, 436.68)/ µL (P = 0.229) and then to 151.08 (108.17, 240.84)/µL (P = 0.007). Auto-HSCT can promote prolonged remission in patients with MM and also overcome some high-risk factors to achieve superior efficacy in group R-ISS II-III. Patients were immunodeficient before transplantation and auto-HSCT facilitated immune reconstitution.
- 7 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessAnalysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma
This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed. Whether in all selected patients or in groups R-ISS II-III, there was a notable increase in the proportion of patients achieving in a very good partial response (VGPR) or better (P < 0.001, P = 0.02) and a complete response (CR) or better (P = 0.007, P = 0.014) after transplantation compared to the pre-transplant status. Post-Transplant Immune Reconstitution Analysis (Baseline vs. Pre-Transplant and Pre-Transplant vs. Post-Transplant): The level of CD19 + B cells, CD20 + B cells, CD22 + B cells, CD3 + T cells, IgG and LMR showed the same change trend, that is, it decreased before transplantation (P < 0.001, P < 0.001, P < 0.001, P < 0.001, PP < 0.001) and then increased significantly after transplantation(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). CD3 + CD4 + T cells from 545.97 (342.11,708.60)/µL to 342.93 (168.38, 475.52)/µL (P < 0.001) and then to 251.48 (188.52, 406.98)/µL (P = 0.348); CD3 + CD8 + T cells from 391.36 (242.19, 563.37)/µL to 337.23 (192.54, 505.96)/µL (P = 0.065) and then to 797.96 (514.49, 1198.03)/µL (P < 0.001), so the CD3 + CD4+/CD3 + CD8 + T cell ratio still remained inverted post-transplant. NK cells changed from 309.86 (206.33, 460.96)/µL to 258.31 (160.75, 436.68)/ µL (P = 0.229) and then to 151.08 (108.17, 240.84)/µL (P = 0.007). Auto-HSCT can promote prolonged remission in patients with MM and also overcome some high-risk factors to achieve superior efficacy in group R-ISS II-III. Patients were immunodeficient before transplantation and auto-HSCT facilitated immune reconstitution.
- Open Access
- 21 October 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (11) , 1750
Correction: Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα–JNK pathway
- 21 October 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (11) , 1750
Open AccessCorrection: Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα–JNK pathway